For all IP practitioners, ranging from those that draft patent specifications, through in house lawyers and outside counsel, that deal with pharmaceuticals, this case is a ‘must read’. For ‘big pharma’ itself, it is a welcome relief following (then) Arnold J’s first instance judgement on how claims with functional and structural limitations should be considered when attacked on the basis of insufficiency, in particular, a lack of plausibility and undue burden.
READ MORE